Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial (2021)

Peer-Reviewed Study · Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, Solari R, Cimino RO, et al. · July 2021

Krolewiecki A et al., 2021-07: Randomized, outcome-assessor-blinded proof-of-concept trial in 45 hospitalized COVID-19 patients in Argentina giving 0.6 mg/kg/day of oral ivermectin for 5 days. Adverse events were similar between arms, so it is one of the few prospective human datasets at 0.6 mg/kg for five consecutive days.

randomized in a 2:1 ratio to standard of care plus oral IVM at 0·6 mg/kg/day for 5 days versus standard of care in 4 hospitals in Argentina

Krolewiecki A et al., 2021-07: Randomized, outcome-assessor-blinded proof-of-concept trial in 45 hospitalized COVID-19 patients in Argentina giving 0.6 mg/kg/day of oral ivermectin for 5 days. Adverse events were similar between arms, so it is one of the few prospective human datasets at 0.6 mg/kg for five consecutive days. C2 high-dose regimen. Study type: proof-of-concept, pilot, randomized, controlled, outcome-assessor-blinded trial; N=45 hospitalized adults, 2:1 ivermectin:standard of care; Argentina (4 hospitals). Dose: oral ivermectin 0.6 mg/kg/day for 5 days, plus standard of care. Comparator: standard of care alone. Funder: grant IP-COVID-19-625 from Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (Argentina) and Laboratorio ELEA/Phoenix, Argentina. Declared conflicts: first author 'reports grants and lecture fees from Laboratorio Elea/Phoenix' (PubMed CoiStatement). Result: no difference in viral load reduction between groups overall; a significant difference in the subgroup with higher median plasma levels; adverse events similar between groups. Quote is the methods sentence from the abstract. Study type: randomized trial.